# Metronidazole

## General description

| | |
|---|---|
| **INN** | Metronidazole |
| **ATC codes** | A01AB17 P01AB01 J01XD01 |
| **Medicine type** | Chemical agent |
| **Antibiotic groups** | A ACCESS |
| **EML status history** | First added in 1977 (TRS 615) for Amoebiasis<br>Changed in 1979 (TRS 641) for Bacterial infection of unspecified site<br>Removed in 2017 (TRS 1006) for Bacterial infection of unspecified site<br>Added in 2017 (TRS 1006) for Intestinal infections due to Clostridioides difficile<br>Changed in 2017 (TRS 1006) for Trichomoniasis<br>Changed in 2021 (TRS 1035) for Necrotising fasciitis<br>Changed in 2023 (TRS 1049) for Peritonitis<br>Changed in 2023 (TRS 1049) for Peritoneal abscess<br>Changed in 2023 (TRS 1049) for Other specified prophylactic measures |
| **Wikipedia** | Metronidazole |
| **DrugBank** | Metronidazole |

## Recommendations

**Section** Access group antibiotics

- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Oral > Solid: 200 to 500 mg tablet
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
- Local > Rectal > Suppository: 500 mg; 1 g
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
- Oral > Solid > tablet: 500 mg; 200 mg; 250 mg; 400 mg
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

**Indications**

**First choice**

Intestinal infections due to Clostridioides difficile | Trichomoniasis | Necrotising fasciitis

**Other indications**

Bacterial infection of unspecified site

**Section** Antiamoebic and antigiardiasis medicines

- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Parenteral > General injections > unspecified: 500 mg in 100 mL vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

**Indications**

Amoebiasis